Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs

First published: 15/07/2024

Last updated: 15/07/2024





Administrative details

Study description

EU PAS number	
EUPAS1000000262	
Study ID	
1000000262	
DARWIN EU® study	
No	
Study countries	
Italy	

Objective: This study aimed at estimating the treated cluster headache (CH) prevalence and describing prescription patterns and direct costs paid by the Italian National-Health-System.

Methods: Through the ReS database (healthcare administrative data collection of a large sample of the

Italian population), adults in treatment for CH (acute therapy with sumatriptan/subcutaneous or oxygen, associated with preventive therapy with verapamil or lithium) were selected. A crosssectional analysis described the prevalence of CH-treated subjects repeated annually in 2013–2017. A longitudinal analysis of patients selected in 2013–2015 and followed for 2 years provided the prescription patterns.

Results: The annual prevalence of CH-treated patients increased from 6.4×100,000 adults in 2013 to 6.7 in 2017. In 2013–2015, 570 patients (80.7% M; mean age 46) treated for CH were found. In 50.4%, the identifying CH treatment was sumatriptan/subcutaneous+verapamil. During follow-up, >1/3 changed the preventive drug and interruption was the most frequent modification, although acute treatments were still prescribed. The mean annual cost/patient ranged from €2,956 to €2,267; pharmaceuticals expenditure represented the 56.4% and 57.3%, respectively.

Conclusions: This study showed an important unmet need among CH patients, carrying a high economic burden that should be considered in the evaluation of the impact of incoming therapies (e.g. Calcitonin-Gene-Related-Peptide antibodies).

Study status

Finalised

Research institutions and networks

Institutions

Fondazione ReS (Ricerca e Salute), CINECA partner	
Italy	
First published: 05/07/2017	
Last updated: 01/10/2025	
Institution Not-for-profit ENCePP partner	

Contact details

Study institution contact

Carlo Piccinni piccinni@fondazioneres.it

Study contact

piccinni@fondazioneres.it

Primary lead investigator

Letizia Dondi

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 12/06/2019

Study start date

Actual: 12/07/2019

Date of final study report

Actual: 11/11/2019

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Eli Lilly

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Healthcare resource utilisation

Data collection methods:

Secondary use of data

Study design:

Retrospective longitudinal cross sectional cohort study.

Main study objective:

This study aimed at estimating the treated cluster headache (CH) prevalence and describing prescription patterns and direct costs paid by the Italian National-Health-System.

Study Design

Non-interventional study design

Cohort

Cross-sectional

Study drug and medical condition

Medical condition to be studied

Population studied

Short description of the study population

Adult patients affected by Cluster headache and treated with specific drugs for acute attack associated with a preventive therapy were selected.

Age groups

Adult and elderly population (≥18 years)

Adults (18 to < 65 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Study design details

Setting

In-hospital and local outpatient settings in public and affiliated with SSN facilities.

Summary results

The annual prevalence of CH-treated patients increased from $6.4\times100,000$ adults in 2013 to 6.7 in 2017. In 2013–2015, 570 patients (80.7% M; mean age 46) treated for CH were found. In 50.4%, the identifying CH treatment was sumatriptan/subcutaneous+verapamil. During follow-up, >1/3 changed the preventive drug and interruption was the most frequent modification, although

acute treatments were still prescribed. The mean annual cost/patient ranged from €2,956 to €2,267; pharmaceuticals expenditure represented the 56.4% and 57.3%, respectively.

Documents

Study publications

Insights into real-world treatment of cluster headache through a large Italian ...

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Database of Fondazione ReS

Data sources (types)

Administrative healthcare records (e.g., claims)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes